These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 26255449)
41. Increased STAT1 Expression in High Grade Serous Ovarian Cancer Is Associated With a Better Outcome. Josahkian JA; Saggioro FP; Vidotto T; Ventura HT; Candido Dos Reis FJ; de Sousa CB; Tiezzi DG; de Andrade JM; Koti M; Squire JA Int J Gynecol Cancer; 2018 Mar; 28(3):459-465. PubMed ID: 29303938 [TBL] [Abstract][Full Text] [Related]
42. [Expression and clinicopathologic significance of CD44v6/CD24 in ovarian serous carcinomas]. Wang A; Lu L; Wang Y; Sun Y; Zhang Y; Guo C; Gu Y; Liu A Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):20-4. PubMed ID: 24713244 [TBL] [Abstract][Full Text] [Related]
43. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases. Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817 [TBL] [Abstract][Full Text] [Related]
44. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas]. Shen XX; Yu L; Bi R; Yang WT Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637 [TBL] [Abstract][Full Text] [Related]
45. EphB3 protein is associated with histological grade and FIGO stage in ovarian serous carcinomas. Gao W; Zhang Q; Wang Y; Wang J; Zhang S APMIS; 2017 Feb; 125(2):122-127. PubMed ID: 28120491 [TBL] [Abstract][Full Text] [Related]
46. Clinicopathological significance of DEK overexpression in serous ovarian tumors. Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407 [TBL] [Abstract][Full Text] [Related]
47. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors]. Wen J; Shi JL; Shen DH; Chen YX; Song QJ Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451 [TBL] [Abstract][Full Text] [Related]
48. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620 [TBL] [Abstract][Full Text] [Related]
49. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions. Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077 [TBL] [Abstract][Full Text] [Related]
50. Flow and image cytometric DNA ploidy, including 5c exceeding cells, of serous borderline malignant ovarian tumors. Correlation with clinicopathologic characteristics. Flezar MS; But I; Kavalar R; Us-Krasovec M Anal Quant Cytol Histol; 2003 Jun; 25(3):139-45. PubMed ID: 12882085 [TBL] [Abstract][Full Text] [Related]
51. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy. Wen YH; Yee H; Goswami S; Shukla PS Int J Gynecol Pathol; 2009 Mar; 28(2):187-92. PubMed ID: 19188814 [TBL] [Abstract][Full Text] [Related]
52. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054 [TBL] [Abstract][Full Text] [Related]
53. Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome. Lokman NA; Pyragius CE; Ruszkiewicz A; Oehler MK; Ricciardelli C Transl Res; 2016 May; 171():83-95.e1-2. PubMed ID: 26925708 [TBL] [Abstract][Full Text] [Related]
54. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor. Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113 [TBL] [Abstract][Full Text] [Related]
55. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Dehari R; Kurman RJ; Logani S; Shih IeM Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266 [TBL] [Abstract][Full Text] [Related]
56. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429 [TBL] [Abstract][Full Text] [Related]
57. [Serous and mucinous epithelial ovarian tumors--a clinicopathologic study of 116 cases]. Giurgea NL; Pitrop M; Mihailovici MS Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):389-94. PubMed ID: 23077925 [TBL] [Abstract][Full Text] [Related]
58. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues]. Zhang Q; He XJ; Ma LP; Li N; Yang J; Cheng YX; Cui H Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):885-90. PubMed ID: 22340095 [TBL] [Abstract][Full Text] [Related]
59. Cancer Stem Cell-Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases. Kenda Šuster N; Frković Grazio S; Virant-Klun I; Verdenik I; Smrkolj Š Int J Gynecol Cancer; 2017 Nov; 27(9):2006-2013. PubMed ID: 28906309 [TBL] [Abstract][Full Text] [Related]
60. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]